Intercalated erlotinib-eribulin "feasible" without added efficacy -
By Lynda Williams, Senior medwireNews Reporter
erlotinib may be interposed with eribulin anti agent tubule mesylate for patients with non-small cell lung cancer (NSCLC) advanced, but it is unlikely to increase the effectiveness of treatment in people without receptor for epidermal growth factor ( EGFR ) activating mutations, research suggests.
The study, published in the Annals of Oncology shows similar results in 63 patients randomly assigned to receive eribulin mesylate 2.0 mg / m 2 day 1 with erlotinib 150 mg on days 2-16 (21 day regimen) and 60 patients who received eribulin mesylate 1.4 mg / m 2 on days 1 and 8 with erlotinib 150 mg on days 15 to 28 (28-day regimen).
All patients had disease progression after receiving at least one platinum-based doublet chemotherapy, but no previous EGFR-tyrosine kinase inhibitor (EGFR TKI) therapy.
The primary endpoint of the trial was objective response rate and it did not differ significantly between patients who received treatment for 21 days and 28 days at 13% against 17% the report Tony Mok, Hong Kong Chinese University, and coauthors.
Schemes 21 and 28 days were also comparable regarding the disease control rate (48 vs 63%) and both the median overall survival (7.6 vs 8.5 months) and progression-free survival (3.5 versus 3.8 months).
analysis showed that the sequential administration of erlotinib did not change the pharmacokinetics of eribulin mesylate and both plans were considered well tolerated. The most common grade 3 or more severe side effects were neutropenia, fatigue and dyspnea.
Mok et al say that while the study met the predefined criteria for the feasibility of the treatment interleaved, the results suggest similar efficacy in Phase II test results for eribulin administered alone, with a rate objective response of 10.0%.
"Our results suggest that the addition of the EGFR TKI erlotinib treatment does not improve
result of eribulin in patients (no selection according to the status of biomarker) with advanced NSCLC, "the authors write.
" this can best be explained by the fact that most patients in this study harbored activation EGFR mutations, "they add, in noting that the importance of these mutations was not clear when the study was designed
Mok and team therefore conclude :. " Future investigation should explore the combination in patients EGFR mutant disease compared with single agent EGFR TKI. "
medwireNews licensed by permission of Springer Healthcare Ltd. © Springer Healthcare Ltd. All rights reserved. None of these parties endorse or recommend any commercial products, services or equipment.
EmoticonEmoticon